MafA is a transcription factor that binds to the promoter in the insulin gene and has been postulated to regulate insulin transcription in response to serum glucose levels, but there is no current in vivo evidence to support this hypothesis. To analyze the role of MafA in insulin transcription and glucose homeostasis in vivo, we generated MafA-deficient mice. Here we report that MafA mutant mice display intolerance to glucose and develop diabetes mellitus. Detailed analyses revealed that glucose-, arginine-, or KCl-stimulated insulin secretion from pancreatic ␤ cells is severely impaired, although insulin content per se is not significantly affected. MafA-deficient mice also display age-dependent pancreatic islet abnormalities. Further analysis revealed that insulin 1, insulin 2, Pdx1, Beta2, and Glut-2 transcripts are diminished in MafA-deficient mice. These results show that MafA is a key regulator of glucose-stimulated insulin secretion in vivo.Insulin is the only polypeptide hormone that is essential for the regulation of blood glucose levels and is synthesized exclusively in ␤ cells of the islets of Langerhans in the pancreas. The molecular mechanisms that control ␤-cell-specific insulin gene transcription are well characterized. Three conserved cis-regulatory elements within the promoter, E1, A3, and RIPE3b/ C1, respectively, appear to be indispensable for proper insulin gene regulation (22,25). Islet-restricted transcription factors Beta2/NeuroD and Pdx1 bind to the E1 and A3 elements in vitro. Gene disruption experiments in mice have revealed that both Beta2 and Pdx1 play critical roles in insulin gene regulation as well as in islet development and function (1,8,21). Furthermore, mutations in both the Beta2 and Pdx1 genes have been identified within populations of patients with type II diabetes (18,29,30).The third regulatory element, RIPE3b/C1, has also been shown to play a critical role in ␤-cell-specific insulin gene transcription as well as in glucose-regulated expression. Previous studies identified a pancreatic ␤-cell-restricted factor, called the RIPE3b1 activator, that is enriched in response to glucose in pancreatic ␤-cell nuclear extracts. Very recently, four groups reported that the RIPE3b1 activator is a member of the Maf family of transcription factors, MafA (10,12,20,26). The large Maf proteins, MafA/L-Maf/SMaf1 (2, 9, 24), MafB (11), c-Maf (23), and Nrl (31), each contain a basic motif followed by a leucine zipper, and all four family members harbor acidic domains that act as transcriptional activation domains. Although a role for MafA in insulin gene regulation was hypothesized, in vivo tests of the hypothesis have not been reported. To elucidate MafA function in insulin gene regulation, we generated MafA-deficient mice. MATERIALS AND METHODSTargeted disruption of the mafA gene. mafA genomic clones were isolated from a 129/SvJ genomic library (Stratagene) using a partial mouse MafA cDNA as a probe. The targeting vector was constructed with the bacterial lacZ gene containing a nuclear loca...

GPR40, one of the G protein-coupled receptors predominantly expressed in pancreatic β-cells, mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. A potent and selective GPR40 agonist is theorized to be a safe and effective antidiabetic drug with little or no risk of hypoglycemia. Cyclization of the phenylpropanoic acid moiety of lead compound 1 produced fused phenylalkanoic acids with favorable in vitro agonist activities and pharmacokinetic profiles. Further optimization led to the discovery of dihydrobenzofuran derivative 9a ([(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate, TAK-875) as a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long-acting drug efficacy. Compound 9a showed potent plasma glucose-lowering action and insulinotropic action during an oral glucose tolerance test in female Wistar fatty rats with impaired glucose tolerance. Compound 9a is currently in clinical trials for the treatment of type 2 diabetes mellitus.

G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/ FFA 1 ) is highly expressed in pancreatic ␤ cells and mediates free fatty acid-induced insulin secretion. This study examined the pharmacological effects and potential for avoidance of lipotoxicity of [(3S)-6-({2Ј,6Ј-dimethyl-4Ј-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemihydrate) (TAK-875), a novel, orally available, selective GPR40 agonist. Insulinoma cell lines and primary rat islets were used to assess the effects of TAK-875 in vitro. The in vivo effects of TAK-875 on postprandial hyperglycemia, fasting hyperglycemia, and normoglycemia were examined in type 2 diabetic and normal rats. In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concentration, consistent with activation of the Gq␣ signaling pathway. The insulinotropic action of TAK-875 (10 M) in INS-1 833/15 and primary rat islets was glucose-dependent. Prolonged exposure of cytokine-sensitive INS-1 832/13 to TAK-875 for 72 h at pharmacologically active concentrations did not alter glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas prolonged exposure to palmitic or oleic acid impaired ␤ cell function and survival. In an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats, TAK-875 (1-10 mg/kg p.o.) showed a clear improvement in glucose tolerance and augmented insulin secretion. In addition, TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg. TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of ␤ cell toxicity.

No abstract

It has been proposed that the cortical actin filament networks act as a cortical barrier that must be reorganized to enable docking and fusion of the synaptic vesicles with the plasma membranes. We identified a novel neuron-associated developmentally regulated protein, designated as Nadrin. Expression of Nadrin is restricted to neurons and correlates well with the differentiation of neurons. Nadrin has a unique structure; it contains a GTPase-activating protein (GAP) domain for Rho family GTPases, a potential coiled-coil domain, and a succession of 29 glutamines. In vitro the GAP domain activates RhoA, Rac1, and Cdc42 GTPases. Expression of Nadrin in NIH3T3 cells markedly reduced the number of the actin stress fibers and the formation of the ruffled membranes, suggesting that Nadrin regulates actin filament reorganization. In PC12 cells, Nadrin colocalized with synaptotagmin in the neurite termini and also with cortical actin filaments in the subplasmalemmal regions. Expression of Nadrin or its mutant composed of the coiled-coil and GAP domain enhanced Ca 2؉-dependent exocytosis of PC12 cells, but a mutant lacking the GAP domain inhibited exocytosis. These results suggest that Nadrin plays a role in regulating Ca 2؉ -dependent exocytosis, most likely by catalyzing GTPase activity of Rho family proteins and by inducing the reorganization of the cortical actin filaments.